Quotidian Technical Highlights on Selected Drug Makers Stocks --

Quotidian Technical Highlights on Selected Drug Makers Stocks -- AbbVie, Biostar Pharma, Bristol-Myers Squibb, and Eli Lilly

Information contained on this page is provided by an independent third-party content provider. Frankly and this Site make no warranties or representations in connection therewith. If you are affiliated with this page and would like it removed please contact pressreleases@franklyinc.com

SOURCE Wall St. Equities

NEW YORK, March. 8, 2018 /PRNewswire/ -- WallStEquities.com strives to bring the best free research to the investment community.  Today we are offering reports on ABBV, BSPM, BMY, and LLY which can be accessed for free by signing up to www.wallstequities.com/registration. WallStEquities.com has selected four major players in the Drug Manufacturers space for review today: AbbVie Inc. (NYSE: ABBV), Biostar Pharmaceuticals Inc. (NASDAQ: BSPM), Bristol-Myers Squibb Co. (NYSE: BMY), and Eli Lilly and Co. (NYSE: LLY). The Pharmaceutical Manufacturing sector consists of establishments that are primarily engaged in one or more of the following: manufacturing biological and medical products; processing botanical drugs and herbs; isolating active medical principles from botanical drugs and herbs; and manufacturing pharmaceutical products intended for internal and external consumption. All you have to do is sign up today for this free limited time offer by clicking the link below.



On Wednesday, shares in North Chicago, Illinois-based AbbVie Inc. recorded a trading volume of 5.29 million shares. The stock ended at $114.72, rising slightly by 0.14% from the last trading session. The Company's shares have gained 4.76% in the last month, 20.48% over the previous three months, and 80.12% over the past year. The stock is trading above its 50-day and 200-day moving averages by 5.41% and 29.87%, respectively. Furthermore, shares of AbbVie, which discovers, develops, manufactures, and sells pharmaceutical products worldwide, have a Relative Strength Index (RSI) of 52.02. 

On February 26th, 2018, AbbVie announced that it will participate in the Barclays Global Healthcare Conference on March 15th, 2018. Bill Chase, Executive Vice President and CFO, will present at 8:00 a.m. CT. A live audio webcast of the presentation will be accessible on the Company's investor relations website. Get the full research report on ABBV for free by clicking below at:


Biostar Pharmaceuticals

Xianyang, China headquartered Biostar Pharmaceuticals Inc.'s stock finished yesterday's session 3.35% higher at $3.39 with a total trading volume of 226,903 shares. The Company's shares have surged 93.71% over the previous three months and 52.70% over the past year. The stock is trading above its 50-day and 200-day moving averages by 17.79% and 78.61%, respectively. Furthermore, shares of Biostar Pharma, which develops, manufactures, and markets over-the-counter and prescription pharmaceutical products for various diseases and conditions in China, have an RSI of 50.91. 

On February 21st, 2018, Biostar Pharma announced its plans to launch a new ecommerce sales platform following nearly ten months of research and preparation. The Company intends to complete this platform by the end of March 2018 and launch it during Q2 FY18. The Company will also include its B2C online shopping mall within the ecommerce sales platform to promote its product-line. The free technical report on BSPM can be accessed at:


Bristol-Myers Squibb

On Wednesday, shares in New York headquartered Bristol-Myers Squibb Co. rose slightly by 0.96%, ending the day at $66.10. The stock recorded a trading volume of 5.92 million shares. The Company's shares have advanced 8.43% in the last month, 5.81% in the previous three months, and 17.34% over the past year. The stock is trading 3.87% and 9.52% above its 50-day and 200-day moving averages, respectively. Moreover, shares of Bristol-Myers Squibb, which discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide, have an RSI of 53.13. 

On February 15th, 2018, research firm Morgan Stanley upgraded the Company's stock rating from 'Equal-Weight' to 'Overweight'.

On March 05th, 2018, Bristol-Myers Squibb announced that it will participate in the Cowen and Company 38th Annual Global Health Care Conference on March 12th, 2018, in Boston. Giovanni Caforio, Chairman and CEO, and Fouad Namouni, head of oncology development, will answer questions about the Company at 2:50 p.m. ET. A live webcast of the session will be available on the Company's investors website. Sign up for free on Wall St. Equities and claim the latest report on BMY at:


Eli Lilly

Indianapolis, Indiana headquartered Eli Lilly and Co.'s shares ended the day 0.32% higher at $77.44 with a total trading volume of 2.24 million shares. The stock is trading 5.48% below its 50-day moving average. Shares of the Company, which discovers, develops, manufactures, and markets pharmaceutical products worldwide, have an RSI of 43.11. 

On February 21st, 2018, Eli Lilly announced that it will participate in the Barclays Global Healthcare Conference on March 14th, 2018. Joshua Smiley, Senior Vice President and CFO, will participate in a fireside chat at 8:30 a.m. ET. A live audio webcast will be available under the "Webcasts & Presentations" section of the Company's Investor website. See the free research coverage on LLY at:


Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

WSE has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@wallstequities.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit



For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: info@wallstequities.com
Phone number: +21-32-044-483
Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

Cision View original content:http://www.prnewswire.com/news-releases/quotidian-technical-highlights-on-selected-drug-makers-stocks----abbvie-biostar-pharma-bristol-myers-squibb-and-eli-lilly-300610580.html

©2017 PR Newswire. All Rights Reserved.

Powered by Frankly